Drug intelligence / Profile preview

Visuflur

Development stage
Unknown
Lead developer
Bioquest Pharmaceuticals
Modality
Small Molecules
Administration
Ophthalmic
01

Overview

Visuflur is a fixed-dose combination ophthalmic solution developed and marketed by Bioquest Pharmaceuticals. It contains Fluorescein Sodium, a diagnostic fluorescent dye, and Lignocaine Hydrochloride (also known as Lidocaine), a local anesthetic of the amide type. The product is specifically formulated for use in ophthalmic diagnostic procedures, most notably Goldmann applanation tonometry, where the anesthetic numbs the cornea and the dye allows for the visualization of the tear film under cobalt blue light. Lignocaine works by blocking voltage-gated sodium channels, thereby preventing the conduction of nerve impulses and providing rapid surface anesthesia. Fluorescein Sodium serves as a tracer that stains damaged corneal tissue and facilitates the measurement of intraocular pressure.

Brand names
Visuflur
Other names
Fluorescein Sodium + Lignocaine HydrochlorideFluorescein Sodium + Lidocaine Hydrochloride
02

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Visuflur.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Visuflur.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call